On the heels of Capital Blue Cross partnering with the Mark Cuban Cost Plus Drug Co. to make lower-cost biosimilar alternatives to Humira and Stelara available to commercial members, CenterWell Pharmacy (a part of Humana Inc.) announced plans to develop end-to-end employer prescription solutions with Cost Plus Drugs.
As part of this collaboration, Cost Plus Drugs’ digital pharmacy SaaS solution, SwiftyRx, also will be used by CenterWell Pharmacy for its medication order intake operations.
According to officials from both companies, the organizations intend to partner on a new employer-based program design in an effort to simplify medication access and lower patient cost by streamlining patient onboarding, automating benefit checks, reducing cost-to-fill, and driving greater operational efficiencies.
Additionally, the SwiftyRx platform is expected to enable CenterWell Pharmacy to have the capability to offer home-delivery pharmacy services to Humana’s eligible workforce enrolled in the Humana Associate Benefit Plan.
“Everyone should be able to get safe, affordable medication,” said Cost Plus Drugs co-founder Mark Cuban. “This collaboration gives Cost Plus Drugs the chance to support more consumers.”
The partnership “reflect[s] an aligned mission to redesign access and affordability in a simplified approach to help patients get the medications they need,” added Bethanie Stein, President of Pharmacy at Humana, including CenterWell Pharmacy.